Table 2. Agreements for ARV medicines with the MPP.
| Licenced product | Patent Holder | Place in Treatment (as per WHO 2015 Guidelines) | Date of licence | Originator Patent Expiry Date | Number of Sub-licensees |
|---|---|---|---|---|---|
| Abacavir paed (ABC) | ViiV Healthcare | First line for pediatrics | Feb-13 | 2018 | 1 |
| Atazanavir (ATV) | Bristol Myers Squibb | Second-line | Dec-13 | 2018 | 5 |
| Cobicistat (COBI) | Gilead Sciences | Pharmacokinetic booster | Jul-11 | 2027 | 8 |
| Darunavira (DRV) | National Institutes of Health | Third-line and second-line | Sep-10 | 2016 | - |
| Dolutegravir (DTG) | ViiV Healthcare | First-line and third-line adults | Apr-14 | 2026 | 9 |
| Elvitegravir (EVG) | Gilead Sciences | New ARV | Jul-11 | 2023 | 7 |
| Emtricitabine (FTC) | Gilead Sciences | First-line and second-line | Jul-11 | 2024 | 9 |
| Lopinavir (LPV) | AbbVie Inc | First line for paediatrics and second-line for adults and paediatrics | Nov-14 Dec-15 |
2026 | 2 |
| Raltegravir paed (RAL) | MSD (Merck in the US and Canada) | Third-line | Feb-15 | 2022 | 2 |
| Ritonavir (RTV) | AbbVie Inc | Pharmacokinetic booster | Nov-14 Dec-15 |
2026 | 2 |
| Tenofovir alafenamide (TAF) | Gilead Sciences | First-line | Jul-14 | 2021 | 9 |
| Tenofovir disoproxil fumarate (TDF) | Gilead Sciences | First-line | Jul-11 | 2018 | 3 |
| Valganciclovirb | Hoffman-La Roche | Opportunistic infection | Aug-13 | 2016 |
a In September 2010, the MPP obtained a licence on darunavir-related patents from the US National Institutes of Health. At the time, however, there were other patents on DRV held by other patent holders.
b Small market size did not warrant generic competition hence price agreement with option of patent licence negotiated with patent holder.